Business
Coherus to Present Data from a Phase 1 Dose Expansion Study of CHS-114, a Cytolytic Antibody Targeting Chemokine Receptor 8 (CCR8), at the 2025 American Association for Cancer Research (AACR) Annual Meeting
REDWOOD CITY, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS), a commercial-stage innovative oncology company, today announced that an abstract highlighting interim data from its ongoing Phase 1 clinical trial evaluating CHS-114, a selective, cytolytic anti-CCR8 antibody, as monotherapy and in combination with toripalimab in patients with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC), has been selected for a poster presentation
About this update from Coherus Oncology, Inc.
[{"type":"image","alt":"Coherus BioSciences, Inc.","displaySize":"","headline":null,"caption":"Coherus BioSciences, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":75,"url":"https://media.zenfs.com/en/globenewswire.com/d87de5d193580fe10b8b8dc96f150ded"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/2xBqfzNhYYlTu.OjLDmoUQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEwNTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/d87de5d193580fe10b8b8dc96f150ded","width":300,"height":75}},"lazy":false},{"type":"text","content":"REDWOOD CITY, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS), a commercial-stage innovative oncology company, today announced that an abstract highlighting interim data from its ongoing Phase 1 clinical trial evaluating CHS-114, a selective, cytolytic anti-CCR8 antibody, as monotherapy and in combination with toripalimab in patients with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC), has been selected for a poster presentation at the upcoming 2025 AACR Annual Meeting, being held April 25-30, 2025, at McCormick Place Convention Center in Chicago, Illinois.","length":635,"tagName":"p"},{"type":"text","content":"AACR 2025 Presentation Details","length":30,"tagName":"p"},{"type":"text","content":"Title: Phase 1 study of anti-CCR8 antibody CHS-114 with and without anti-PD-1 antibody toripalimab in patients with advanced solid tumorsLead Author: Francis Worden, M.D., University of MichiganAbstract #: CT038Poster Session: Phase 0 and Phase 1 Clinical TrialsPoster Section 49: Poster board 17Date and Time: Monday, April 28, 2025, 9:00 a.m. – 12:00 p.m. CDT","length":371,"tagName":"p"},{"type":"text","content":"About the CHS-114 Phase 1 StudyThe Phase 1 study (NCT05635643) is a dose escalation, dose optimization and expansion study evaluating CHS-114 as a monotherapy and in combination with toripalimab, a next generation PD-1 inhibitor. Cohort 1a enrolled 20 patients with advanced solid tumors including 2 patients with HNSCC and evaluated multiple dose levels (5-1200 mg) of CHS-114 monotherapy. Cohort 1b evaluated two pharmacologically active doses of CHS-114 monotherapy in 12 HNSCC patients with paired tumor biopsies. Cohort 2 evaluated two pharmacologically active doses of CHS-114 with toripalimab in 7 patients. Primary objective...